PTC Therapeutics (NASDAQ:PTCT) EVP Sells $633,800.00 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 10,000 shares of PTC Therapeutics stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $63.38, for a total value of $633,800.00. Following the completion of the transaction, the executive vice president directly owned 79,944 shares of the company’s stock, valued at $5,066,850.72. This represents a 11.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Lee Scott Golden also recently made the following trade(s):

• On Wednesday, February 18th, Lee Scott Golden sold 2,484 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.36, for a total transaction of $172,290.24.
• On Thursday, January 8th, Lee Scott Golden sold 866 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total value of $66,205.70.
• On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $49,742.16.
• On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $103,113.00.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT traded up $5.58 during mid-day trading on Monday, reaching $68.40. 2,494,745 shares of the company’s stock were exchanged, compared to its average volume of 1,317,297. The firm has a market capitalization of $5.66 billion, a price-to-earnings ratio of 8.84 and a beta of 0.51. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50. The business’s fifty day moving average price is $72.77 and its 200-day moving average price is $69.45.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The firm had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. During the same quarter last year, the company earned ($0.85) earnings per share. The company’s quarterly revenue was down 22.7% compared to the same quarter last year. Analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Institutional Trading of PTC Therapeutics

Several large investors have recently modified their holdings of PTCT. UMB Bank n.a. purchased a new position in shares of PTC Therapeutics during the fourth quarter valued at approximately $26,000. Smartleaf Asset Management LLC lifted its stake in shares of PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. boosted its position in shares of PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares in the last quarter. Comerica Bank grew its stake in PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the period. Finally, Salomon & Ludwin LLC purchased a new position in PTC Therapeutics during the fourth quarter valued at $41,000.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PTCT. Wall Street Zen cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Morgan Stanley lifted their price target on PTC Therapeutics from $90.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd. Royal Bank Of Canada reduced their price objective on shares of PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating for the company in a research note on Friday, February 20th. Barclays restated an “overweight” rating and set a $120.00 target price on shares of PTC Therapeutics in a research report on Monday, February 23rd. Finally, Bank of America decreased their price target on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $82.79.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.